QuatRx Announces Further Positive Phase 3 Results For Ophena(TM) (Ospemifene Tablets) In Postmenopausal Vaginal Atrophy

QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, announced positive top-line efficacy results from the first of two patient cohorts in its second pivotal Phase 3 trial of the investigational compound, Ophena(TM) (ospemifene tablets), for the treatment of postmenopausal vulvovaginal atrophy (VVA). The Company has also successfully completed two long term safety extension studies from its first pivotal Phase 3 studies.

source : www.medicalnewstoday.com

Related News:

• Aethlon Medical Announces Presentation Of Hepatitis-C (HCV)…
• Adipose-Derived Stem And Regenerative Cells Show Potential In…
• Analysis of TB treatment studies identifies gaps in guidelines
• Special Article: Some Flowers in Ophthalmology
• Very Small Head Size Could Signal Problems in Newborns
• Can parasites cause anemia and undernutrition in Northern Rwanda?
• Exercise can extend survival even in ‘oldest old’
• Water quality in orbit
• FAST: Fluid index more accurate than weight monitoring in predicting worsening HF
• Families ‘kept in the dark’ as doctors make life-or-death decisions

Details :
Submited at Thursday, July 30th, 2009 at 8:01 am on Endocrinology by Gillan
Comment RSS 2.0 - leave a comment - trackback